西黄丸联合同步放化疗治疗局部宫颈癌的临床研究
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

基金项目:

国家自然科学基金项目——基于miR-7/FAK途径探讨西黄丸抑制结肠癌细胞上皮-间质转化(EMT)的机制(编号:81503526);广东省自然科学基金项目——西黄丸通过miR-7/PARP-1信号轴抑制结肠癌细胞上皮-间质转化(EMT)(编号:2015A030310448)


Effect of Xihuang Pills Combined with Concurrent Chemoradiotherapy on Locally Advanced Cervical Cancer
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察西黄丸联合同步放化疗治疗局部晚期宫颈癌的近期疗效,严重不良反应和对患者生活质量及免疫状态的影响。方法:选择已发生无法手术切除的局部晚期宫颈癌患者62例,随机分为2组,对照组予同步放化疗,观察组予西黄丸联合同步放化疗,比较2组近期疗效、严重不良反应、生活质量,并比较2组患者细胞免疫状态的差异。结果:观察组与对照组近期有效率比较无统计学意义(P>0.05);观察组在延缓肿瘤进展时间、减少(血液、放射性损伤及疲劳等)不良反应、提高生活质量及抗肿瘤细胞免疫状态等方面优于对照组(P均<0.05)。结论:西黄丸联合同步放化疗可改善局部晚期宫颈癌患者的生活质量,降低常见的严重不良反应,并能在一定程度上激活抗肿瘤细胞免疫反应。

    Abstract:

    To observe the effect of Xihuang pills combined with concurrent chemoradiotherapy on locally advanced cervical cancer.Methods:Sixty-two patients with locally advanced cervical cancer were randomly divided into two groups: patients in control group were treated with concurrent chemoradiotherapy, and patients in observation group were treated with Xihuang pills combined with concurrent chemoradiotherapy. Indexes as the objective response rate (RR), toxicities, quality of life (QOL), and cellular immune status were compared.Results:There was no significant difference in RR between the two groups (P>0.05). Observation group was superior to control group in the aspects of TTP, toxicity, QOL and anti-tumor immune(P<0.05).Conclusion:Xihuang pills combined with concurrent chemoradiotherapy has advantages in improving QOL, reducing side effects, and activating anti-tumor immune response in patients with locally advanced cervical cancer.

    参考文献
    相似文献
    引证文献
引用本文

陈清梅,李纪强.西黄丸联合同步放化疗治疗局部宫颈癌的临床研究[J].世界中医药,2016,(07).

复制
相关视频

分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2015-09-19
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2016-08-10
  • 出版日期:
文章二维码